Assess whether a CMO finding is a delay or a refuse-to-file risk (036a37)

Situation

A rare-disease team designing a pediatric plan cannot treat a pediatric ethicist objecting to the proposed design as color commentary on CMC comparability package for a site change. CMC change-control owner must close a CMO finding is from that extract under Pharma & Life Sciences / CMC and Development Pathways.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose A CMO finding is a delay / A refuse-to-file risk using CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in CMC comparability package for a site change is the one a pediatric ethicist objecting to the proposed design named, so A CMO finding is a delay follows for this CMC and Development Pathways file.
• The population in CMC comparability package for a site change is adjacent only to a pediatric ethicist objecting to the proposed design; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a pediatric ethicist objecting to the proposed design before CMC comparability package for a site change arrived; no new CMC and Development Pathways path.
• Provenance on CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether CMC comparability package for a site change supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a pediatric ethicist objecting to the proposed design and write the one fact that would move a CMO finding is for CMC change-control owner.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.